Edgewise Therapeutics (NASDAQ:EWTX) Rating Lowered to “Sell” at Wall Street Zen

Edgewise Therapeutics (NASDAQ:EWTX) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

A number of other equities analysts have also recently issued reports on EWTX. JPMorgan Chase & Co. raised their price objective on shares of Edgewise Therapeutics from $33.00 to $34.00 and gave the company an “overweight” rating in a research note on Friday, November 14th. Evercore reissued an “outperform” rating and issued a $45.00 price target on shares of Edgewise Therapeutics in a research note on Thursday. Stifel Nicolaus set a $25.00 price target on Edgewise Therapeutics in a research report on Thursday. Wedbush dropped their price objective on Edgewise Therapeutics from $35.00 to $32.00 and set an “outperform” rating for the company in a report on Friday, November 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Edgewise Therapeutics in a research note on Wednesday, January 21st. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $36.36.

Edgewise Therapeutics Stock Up 2.6%

Shares of EWTX stock opened at $30.44 on Friday. The firm has a market cap of $3.27 billion, a price-to-earnings ratio of -18.67 and a beta of 0.26. Edgewise Therapeutics has a 12 month low of $10.60 and a 12 month high of $31.82. The stock has a 50-day moving average price of $27.62 and a 200 day moving average price of $21.27.

Edgewise Therapeutics (NASDAQ:EWTX) last issued its earnings results on Thursday, February 26th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.04). Sell-side analysts predict that Edgewise Therapeutics will post -1.45 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Edgewise Therapeutics news, Director Badreddin Edris sold 115,471 shares of Edgewise Therapeutics stock in a transaction dated Wednesday, January 21st. The stock was sold at an average price of $29.44, for a total transaction of $3,399,466.24. Following the transaction, the director directly owned 19,820 shares in the company, valued at approximately $583,500.80. The trade was a 85.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 23.20% of the company’s stock.

Institutional Investors Weigh In On Edgewise Therapeutics

A number of hedge funds have recently modified their holdings of EWTX. Seven Fleet Capital Management LP acquired a new position in shares of Edgewise Therapeutics in the 4th quarter valued at approximately $50,000. Jones Financial Companies Lllp bought a new position in Edgewise Therapeutics in the first quarter valued at approximately $47,000. Bessemer Group Inc. lifted its stake in Edgewise Therapeutics by 1,170.3% in the third quarter. Bessemer Group Inc. now owns 2,350 shares of the company’s stock valued at $38,000 after buying an additional 2,165 shares in the last quarter. Steward Partners Investment Advisory LLC boosted its holdings in shares of Edgewise Therapeutics by 23.9% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 2,854 shares of the company’s stock valued at $71,000 after buying an additional 550 shares during the period. Finally, Canada Pension Plan Investment Board bought a new stake in shares of Edgewise Therapeutics during the second quarter worth $45,000.

Key Stories Impacting Edgewise Therapeutics

Here are the key news stories impacting Edgewise Therapeutics this week:

• Positive Sentiment: Multiple near‑term clinical catalysts could drive upside: management flagged CIRRUS‑HCM 12‑week data for EDG‑7500 and Phase 1 healthy‑adult data for EDG‑15400 (with planned heart‑failure studies) expected in H1 2026, and pivotal GRAND CANYON results for sevasemten in Becker muscular dystrophy anticipated in Q4 2026. These readouts materially de‑risk the pipeline and are likely the main reason investors are buying the stock. PR Newswire: Q4 & Full Year 2025 Results
• Positive Sentiment: Company increased R&D investment in Q4, signaling management is funding those near‑term trials and pivotal work — a positive for long‑term value creation if the upcoming readouts are favorable. BizWest: R&D boost
• Neutral Sentiment: Analyst modeling: HC Wainwright published quarterly EPS forecasts for 2026 (Q1 -$0.43, Q2 -$0.47, Q3 -$0.51, Q4 -$0.60; full‑year -$1.45). These estimates reinforce expectations of continued operating losses as the company advances trials; they provide a near‑term earnings framework but don’t change the pipeline narrative. MarketBeat: HC Wainwright estimates
• Neutral Sentiment: Valuation discussion: recent coverage (e.g., Yahoo Finance) examines EWTX’s strong multi‑year returns and recent momentum, useful for investors assessing whether current share price already reflects upcoming catalysts. Yahoo Finance: Valuation piece
• Negative Sentiment: Q4 earnings miss and near‑term financial drag: Edgewise reported EPS of ($0.47) for the quarter, missing the consensus ($0.43). The combination of the miss and higher R&D spend increases short‑term risk and means more funding will likely be required before positive cash flow. Press Release: Q4 Results

About Edgewise Therapeutics

Edgewise Therapeutics, Inc (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. The company leverages its expertise in small-molecule chemistry and ion channel biology to address severe, unmet medical needs, particularly in the areas of kidney disorders and neuromuscular diseases.

At the core of Edgewise’s pipeline is EWTX-101, a novel, orally available inhibitor of TRPC5, a calcium channel implicated in nephrotic syndromes such as focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases.